血清PSA和性激素六项联合检测与前列腺良恶性疾病的关系

为探讨血清前列腺特异性抗原(PSA)、游离前列腺特异性抗原(fPSA)、f/t PSA及性激素六项在前列腺疾病中的应用价值,用放射免疫法(RIA)测定72例前列腺增生(BPH)患者和40例前列腺癌(Pca)患者血清中的PSA、fPSA、f/t PSA及性激素六项[睾酮(T)、孕酮(P)、雌二醇(E2)、垂体泌乳素(PRL)、促黄体生成素(LH)、促卵泡成熟激素(FSH)]水平.结果表明,BPH组的性激素T、E2、PRL、LH、FSH水平均明显低于Pca组,Pca组中P水平明显低于BPH组;BPH组fPSA、f/t PSA比值均明显高于Pca组.提示前列腺良恶性疾病(BPH和Pca)与激素水平失调有关,血清tPSA、fPSA均是诊断Pca和BPH的重要指标,与血清f/t PSA联合测定,可提示哪些患者需要进行前列腺TRUS,并可提高Pca早期检出率.     

良性前列腺增生患者血清激素水平与前列腺体积的关系

目的 良性前列腺增生症(benign prostatic hyperplasia, BPH)是引起老年男性排尿困难的常见疾病,极大地影响了患者生活质量。本文旨在研究BPH患者激素水平与前列腺体积之间的关系,探索与BPH进展有重要关系的激素,为BPH治疗靶点提供新的思路。方法 我们对168例BPH患者,全部进行了前列腺超声检查,通过Terris公式计算前列腺体积(prostate volume, PV),用液相色谱质谱联用技术测定BPH患者血清激素水平,通过化学发光法检测BPH患者血清PSA和fPSA水平。结果 最终纳入117例数据,通过对BPH的年龄、PV、激素和PSA水平进行Spearman相关性分析,发现PV与PSA呈正相关(r=0.455,P<0.01),与DHEAS呈负相关(r=-0.28,P<0.01);年龄与DHEAS呈负相关(r=-0.288,P<0.01),与PV呈正相关(r=0.233,P<0.05);DHT水平与PSA呈正相关(r=0.325,P<0.01);对PV与激素进行了多重线性回归分析,结果显示在未调整年龄之前,DHT、DHEA...     

老年人PSA水平与前列腺疾病的关系研究

目的:观察老年男性血清PSA水平与前列腺疾病的相关性.方法:采用放射免疫分析,分别对845例老年人和前列腺良性疾患与前列腺癌病人进行了血清PSA的检测,并与40例正常人比较.结果:老年体检组中各年龄段的血清PSA平均水平明显升高,显著高于正常对照组(P＜0.01);前列腺癌患者血清PSA水平显著高于前列腺良性疾患组和正常对照组(P＜0.01),前列腺良性疾患组又明显高于正常对照组(P＜0.01).结论:检测老年男性血清PSA水平有助于鉴别诊断前列腺癌和前列腺良性疾病及泌尿系统等疾病,但PSA不能成为唯一诊断前列腺癌的血清学指标.     

前列腺增生症患者合并的前列腺炎症对血清前列腺特异性抗原的影响

目的：探讨前列腺增生症合并的前列腺炎症对患者血清PSA的影响。方法纳入2006年9~12月在四川大学华西医院行经尿道前列腺电切术的前列腺增生症患者52例，术前检查经直肠前列腺B超，检测血清前列腺特异性抗原，记录年龄和是否存在急性尿潴留；术中取切取的前列腺组织采用real-time PCR检测前列腺感染与否。采用Logistic多元回归方法，纳入尿潴留、前列腺感染、前列腺体积和年龄等因素的同时，分析前列腺腺周炎症、前列腺腺体炎症是否与血清前列腺特异性抗原浓度有关。结果前列腺腺周炎症、前列腺体积与血清PSA升高有关(值分别为0.027和0.001)。结论除了前列腺体积外，前列腺腺周炎症是前列腺增生症患者血清PSA升高的危险因素。     

中、老龄男性血清睾酮和皮质醇含量变化规律的研究

目的：研究中老年男性血清睾酮和皮质醇含量变化及规律。方法：５８１例４０岁以上健康男性以每１０年为一年龄组,分为４组。以２０～３９岁健康男性１１０例作为对照组。均于上午８～１０时静脉采血,分离血清,应用放免分析方法检测血清睾酮和皮质醇含量。结果：（１）４０岁以上各组血清睾酮含量与年轻组比较明显下降（Ｐ＜００１）,血清皮质醇含量逐渐增加,与对照组比较均差异显著（Ｐ＜００１）;（２）血清睾酮与皮质醇含量呈显著负相关（ｒ＝－０．３０９６,Ｐ＜００１）。结论：随增龄睾丸的内分泌功能逐渐下降,而肾上腺皮质功能则发生与之相反的变化     

PCa患者血清睾酮和PSA检测及治疗前后的变化

本文通过对152例前列腺癌(PCa)患者治疗前后的血清PSA和睾酮的检测,并与35例无前列腺疾病的中老年健康男性的血清PSA和睾酮进行对照分析,探讨其在PCa诊断、治疗及预后中的价值。1资料和方法1.1对象1.1.1病人组:152人,男性,均为2008年6月～2012年1月期间在我院门诊及住院诊断治疗的病人,年龄(50～80)岁,平均71.58岁。病人主要为体检时发现PSA升     

老龄男性血浆性激素与T淋巴细胞功能的关系

为探讨老年男性人群血浆雌二醇及睾酮含量与Ｔ淋巴细胞功能的相关性,以５０岁以上男性为研究对象,应用放射免疫法和生物测定法分别检测了血浆睾酮、雌二醇含量和Ｔ淋巴细胞功能。①随增龄血浆雌二醇（Ｅ２）含量明显升高,睾酮（Ｔ）含量显著降低,二者呈明显的负相关关系,Ｅ２／Ｔ比值随增龄明显增大;②外周血淋巴细胞丝裂原反应性和血浆ＩＬ－２活性随增龄而下降;③Ｅ２／Ｔ比值与外周血淋巴细胞丝裂原反应性和血浆ＩＬ－２活     

前列腺特异抗原研究进展

前列腺特异抗原(prostate specific antigen, PSA)是与前列腺癌相关的一种抗原.它是公认的诊断前列腺癌的较好的肿瘤标志物.前列腺癌在男性所有类型癌中占10%～20%,是男性最常见的癌肿.该病进展缓慢,是威胁50岁以上男性生命的主要癌症,在西方国家占男性死亡率的第二位.流行病学调查表明,随着我国居民生活水平的改善,环境污染的加剧以及饮食结构的改变,前列腺癌的发病率日趋上升,已引起临床上的高度重视.美国FDA已批准将PSA检测作为50岁以上男性的普查指标.研究显示,PSA测定在早期诊断前列腺癌上要优于直肠指检.正常男性的PSA值＜4μg/L.     

前列腺增生症对前列腺特异抗原的影响

前列腺特异抗原(prostate specific antigen, PSA)是目前公认的诊断前列腺癌的肿瘤标志物,但在其他前列腺疾病如良性前列腺增生症(BPH)、炎症等病例中亦有不同比例的阳性率,致使其特异性和临床使用受到一定的限制.为此,于1993年3月至1998年1月测定了68例BPH患者的血清PSA水平,观察前列腺体积和年龄对PSA的影响. 资料与方法 1 临床资料 1.1 BPH组 48例,年龄56～79岁,平均年龄66.7岁.均经耻骨上前列腺摘除术后病理确诊,记录标本重量.     

血清PSA测定在前列腺疾病诊断中的意义

我们应用放射免疫分析法(RIA),检测了100例各种前列腺病患者血清前列腺特异性抗原(PSA)个量,以观察PSA水平的变化,现将结果报告如下。 材料和方法 一、对象:100例前列腺疾病患者,年龄为29～70岁,平均46岁。其中前列腺癌18例,前列腺增生31例,前列腺炎51例。所有患者均经临床、实验室检查、影像检查或病理组织学检查等确诊。另取50例健康的男性作为正常对照组。年龄在22～56岁之间。 二、方法:所有被检者均抽空腹静脉血,立即分     

Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer.

This cross-sectional study was undertaken to determine whether serum hormones (free testosterone, androstenedione, luteinizing hormone, or prolactin) have any influence on serum prostate specific antigen (PSA) levels in patients with stage A-C prostate cancer. Blood samples were collected prior to any treatment in 36 patients; in 19 (group 1), three blood samples were collected 10 minutes apart between 9:00 AM and 9:30 AM for each patient and pooled together to avoid diurnal and episodic variation in serum testosterone values. In the remaining patients, only one sample could be collected (group 2). Free testosterone, androstenedione, luteinizing hormone, prolactin, and PSA levels were determined with appropriate radioimmunoassay techniques. Statistical analyses were performed separately for groups 1 and 2, and then with pooled data. None of the hormones in any of the analyses showed any association to serum PSA values except for prolactin for the pooled data and for group 2. This statistical significance for prolactin disappeared on multivariate analysis. There were 21 African-American men and 15 whites in the study; no racial differences in hormonal levels were found except for lower luteinizing hormone levels in African Americans in group 2 and pooled data. No differences were found between group 1 and group 2 in the mean serum prolactin and luteinizing hormone values. Serum free testosterone, androstenedione, and luteinizing hormone appeared to have no influence on serum PSA values in nonmetastatic cancer patients. Serum prolactin values were inversely associated with PSA values in univariate analysis for the pooled data; this disappeared in multivariate analysis. Unlike other studies that found higher serum testosterone levels in African-American college students than whites, no such differences were seen in this age group. Luteinizing hormone was lower in African-American men than in whites in the pooled study population. Further studies are needed to clarify our findings.     

Association of serum EPCA-2 level with prostate cancer in Chinese Han population

Background: Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has not been clarified in Chinese Han population. Methods: EPCA-2 and prostate-specific antigen (PSA) levels in serum were detected by enzyme linked immunosorbent assay in 116 patients with prostate cancer (PCa), 342 patients with benign prostatic hyperplasia (BPH), and 174 healthy controls (Control) in Chinese population. Associations of serum EPCA-2 and PSA level with prostate diseases were analyzed by ANOVA. Comparison of diagnostic effect for prostate cancer between EPCA-2 and PSA was evaluated by Receiver Operator Curve, Chi-square test, and others. Results: Serum EPCA-2 and PSA levels in PCa group were significantly higher than BPH and Control group (EPCA-2: F=200.05, P<0.01; PSA: F=210.65, P<0.01). However, EPCA-2 levels in the prostate cancers with different pathological grade were no significant difference. Furthermore, for detection of prostate cancer, EPCA-2 had a sensitivity of 81.9% and a specificity of 87.6%. Conclusions: Serum EPCA-2 could be used as a potential serological marker to diagnose prostate cancer in Chinese Han population, which was more specific than PSA and did not associate with pathological grades of prostate cancer.     

联检血清性激素水平在继发性闭经中的临床意义

目的 :通过对 10 0例继发性闭经患者血清性激素水平的测定和分析 ,判断继发性闭经的类型 ,为进一步检查和治疗提供可靠的依据。方法 :采用电化学发光免疫分析法 ,定量检测患者血清性激素水平包括雌二醇 (E2 )、孕酮 (P)、促卵泡刺激素 (FSH)、黄体生成素 (LH)、垂体泌乳素 (PRL)和睾酮 (T)。结果 :在 10 0例患者中有 78例血清性激素水平异常。FSH、LH和PRL明显升高 ,与对照组比较具有显著性差异 (P <0 0 1) ,E2 有所下降 (P <0 0 5 ) ,P和T无明显改变。结论 :联检血清性激素水平在继发性闭经中具有重要意义 ,可以判断继发性闭经的类型 ,为进一步检查和治疗提供可靠的依据。     

Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia.

Prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) are the tumor markers for monitoring disease progression or improvement in patients with prostate adenocarcinoma. The clinical utility of PSA and PAP for early detection of prostate adenocarcinoma, however, requires distinction between prostate adenocarcinoma and prostate nodular hyperplasia. The serum PSA and PAP levels were measured in 20 men with histologically proven prostate adenocarcinoma and 28 men with histologically proven prostate nodular hyperplasia. Patients'' blood samples were collected 1 to 7 days prior to the prostate examination, which included a rectal digital examination, transurethral resection, cytoscopy, and prostate biopsy. Sensitivity, specificity, and predictive values of positive and negative results for the discrimination of prostate adenocarcinoma from prostate nodular hyperplasia were 85%, 89%, 85%, and 29%, respectively, for serum PSA (cutoff level: 10 ng/mL) and 40%, 96%, 89%, and 69%, respectively, for serum PAP (cutoff level: 10 ng/mL). Results indicate that marked elevation of serum PSA suggests prostate adenocarcinoma and that serum PSA can discriminate prostate adenocarcinoma from prostate nodular hyperplasia better than serum PAP.     

Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels

We evaluated the correlations between BMI, fasting glucose, insulin, testosterone level, insulin resistance, and prostate size in non-diabetic benign prostatic hyperplasia (BPH) patients with normal testosterone levels. Data from 212 non-diabetic BPH patients with normal testosterone levels, who underwent transurethral resection of the prostate (TURP) due to medical treatment failure, were evaluated retrospectively. Patients with prostate specific antigen (PSA) levels of ≥ 3 ng/mL underwent multicore transrectal prostate biopsy before TURP to rule out prostate cancer. Patients with diabetes mellitus (DM) or serum testosterone levels of < 3.50 ng/mL were excluded from analysis. Correlations between clinical and laboratory parameters were determined. Prostate size correlated positively with age (r = 0.227, P < 0.001), PSA (r = 0.510, P < 0.001), and fasting glucose level (r = 0.186, P = 0.007), but not with BMI, testosterone, insulin level, or insulin resistance (each P > 0.05). Testosterone level inversely correlated with BMI (r = -0.327, P < 0.001), insulin level (r = -0.207, P = 0.003), and insulin resistance (r = -0.221, P = 0.001), but not with age, prostate size, PSA, or fasting glucose level (each P > 0.05). Upon multiple adjusted linear regression analysis, prostate size correlated with elevated PSA (P < 0.001) and increased fasting glucose levels (P = 0.023). In non-DM BPH patients with normal testosterone levels, fasting glucose level is an independent risk factor for prostate hyperplasia.     

Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy

Prostate-specific antigen (PSA) is a sensitive and specific serum marker for monitoring disease activity in men with prostatic carcinoma. Despite reports of elevation of levels of this analyte in men with benign prostatic hyperplasia, no information is available correlating the serum levels with the actual prostatic abnormalities in men having prostatectomy for presumed benign disease. In the present investigation, the authors compared preoperative serum PSA levels with prostate disease in 81 men with bladder outlet obstruction. Five pathologic groups were found: incidental high-grade carcinoma (n = 3), low-grade carcinoma (n = 11), acute inflammation (n = 16) with or without chronic inflammation, Prostatic intraepithelial neoplasia (PIN) (n = 25), and benign hyperplasia (n = 26). Serum PSA levels were significantly elevated in both low- and high-grade carcinoma, acute inflammation, and PIN when compared with the patients with benign hyperplasia with and without chronic inflammation. Within the four groups with elevated levels, use of PSA levels could separate only the high-grade cancer patients who were subsequently shown to have metastatic disease. Only one patient with simple hyperplasia had PSA levels in the abnormal range.     

The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer

The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.     

Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.

To evaluate a relationship between Gleason scores of histopathology of prostate carcinoma and concurrent serum prostate-specific antigen (PSA) and prostate acid phosphatase (PAP) values, 65 men with prostate carcinoma were studied. These patients' cumulative Gleason scores were obtained by totaling the primary and secondary patterns, resulting in two groups: 42 patients received high (6-10) and 23 received low (2-5) Gleason scores. Serum PSA and PAP values were measured by radioimmunometric assay 1 to 7 days before surgical procedures or biopsy for prostate carcinoma. Mean serum PSA for patients in the high Gleason score group was 134.39 ng/mL (normal range: 0 to 4), and the mean serum PSA for patients in the low Gleason score group was 23.62 ng/mL. Mean serum PAP for patients with high scores was 28.08 ng/mL (normal range: 0 to 5), and the mean serum PAP for patients with low scores was 18.19 ng/mL. Patients with high Gleason scores showed significantly greater elevation of serum PSA than those with low Gleason scores (P = .047), using two samples to test for groups having unequal variants. Prostate acid phosphatase levels of patients with high scores were not significantly higher than the levels in patients with low scores (P = .60). These results indicate that PSA levels but not PAP levels correlate with Gleason scores.     

Transient hypogonadotrophic hypogonadism in males with acute toxoplasmosis: suppressive effect of interleukin-1 beta on the secretion of GnRH

BACKGROUND: In September 2002, an outbreak of toxoplasmosis was noted in a male boarding high school on the Aegean coast of Turkey. We have focused our efforts to investigate the sex hormones in this population. METHODS: Blood samples were collected from 40 male patients, 17-18 years old, who also had positive titres of antibody to Toxoplasma gondii. Serum FSH, LH, free testosterone (FT), total testosterone (TT), interferon-gamma (IFN-gamma), interleukin-1beta (IL-1beta) and macrophage-inflammatory protein-1alpha (MIP-1alpha) concentrations were measured in all patients and 20 control subjects. Initially, the patients were divided on the basis of the levels of sex hormones into the following groups: patients who had normal sex hormone levels (n = 31) as group A and patients with low sex hormone levels (n = 9) as group B. RESULTS: IL-1beta levels were found to be higher in group B patients than group A. The levels of IL-1beta correlated significantly in a negative manner with FSH, LH, FT and TT in all patients with acute toxoplasmosis (n = 40). CONCLUSIONS: Acute toxoplasma infection may cause temporary hypogonadotrophic gonadal insufficiency regardless of the course of the disease.